A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck.
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2013
At a glance
- Drugs Lapatinib (Primary)
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- 03 Jun 2013 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 06 Aug 2007 Status change from recruiting to suspended.
- 24 Aug 2005 New trial record.